- Home
- OGEN vs KZIA Comparison
OGEN vs KZIA Comparison
Compare OGEN & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OGEN
- KZIA
- Stock Information
- Founded
- OGEN 1996
- KZIA 1994
- Country
- OGEN United States
- KZIA Australia
- Employees
- OGEN N/A
- KZIA N/A
- Industry
- OGEN Biotechnology: Pharmaceutical Preparations
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- OGEN Health Care
- KZIA Health Care
- Exchange
- OGEN Nasdaq
- KZIA Nasdaq
- Market Cap
- OGEN 4.6M
- KZIA 5.1M
- IPO Year
- OGEN N/A
- KZIA 1999
- Fundamental
- Price
- OGEN $4.13
- KZIA $6.10
- Analyst Decision
- OGEN
- KZIA Strong Buy
- Analyst Count
- OGEN 0
- KZIA 2
- Target Price
- OGEN N/A
- KZIA $57.50
- AVG Volume (30 Days)
- OGEN 656.3K
- KZIA 2.6M
- Earning Date
- OGEN 08-08-2025
- KZIA 07-07-2025
- Dividend Yield
- OGEN N/A
- KZIA N/A
- EPS Growth
- OGEN N/A
- KZIA N/A
- EPS
- OGEN N/A
- KZIA N/A
- Revenue
- OGEN N/A
- KZIA $1,549,158.00
- Revenue This Year
- OGEN N/A
- KZIA N/A
- Revenue Next Year
- OGEN N/A
- KZIA N/A
- P/E Ratio
- OGEN N/A
- KZIA N/A
- Revenue Growth
- OGEN N/A
- KZIA 248983.08
- 52 Week Low
- OGEN $3.12
- KZIA $2.86
- 52 Week High
- OGEN $75.60
- KZIA $79.00
- Technical
- Relative Strength Index (RSI)
- OGEN 47.04
- KZIA 50.96
- Support Level
- OGEN $3.41
- KZIA $5.83
- Resistance Level
- OGEN $4.85
- KZIA $9.60
- Average True Range (ATR)
- OGEN 0.58
- KZIA 1.19
- MACD
- OGEN 0.01
- KZIA -0.29
- Stochastic Oscillator
- OGEN 42.49
- KZIA 18.39
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.